Lumosa Announces Details of Upcoming Institutional Investor Conference

Lumosa and Center Lab to Hold Joint Investor Press Conference for Material Announcement on 24/11/29

LUMOSA’s LT3001 Phase 2 Trial in China Reaches Important Milestone

300 Subjects completed the trial process

Lumosa's LT3001 Receives UK Phase 2 Trial Approval

Obtained trial approvals in 7 European countries

Lumosa to Participate the 2024 BIO International Convention

Center Lab Group Executive Takes Helm as New Lumosa Chairman to Drive Global Licensing of LT3001 Stroke Candidate

Clinical Enrollment on Track, Data Readout Expected by Year-End